Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients.

These analyses confirm that an important gap exists between real-life patients and clinical trials populations in COPD, which limits the relevance of results and therefore should be considered when grading levels of evidence and designing future studies.